FATE Q2 2020 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$142M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+94.0% YoY

Gross Profit

-$21M-388.0% margin

Operating Income

-$29M-525.3% margin

Net Income

-$28M-513.7% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+117.3%

Cash Flow

Operating Cash Flow

$39M

Free Cash Flow

$38M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$654M

Total Liabilities

$179M

Stockholders' Equity

$474M

Cash & Equivalents

$433M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+94.0%
Gross Profit	-$21M	-$19M	-12.7%
Operating Income	-$29M	-$24M	-19.2%
Net Income	-$28M	-$23M	-19.6%